ROIVANT SCIENCES LTD.
Ownership & governance
Executives 5Directors 8Avg age 48Avg tenure 5.5y
MG
Matthew Gline
Chief Executive Officer
Age 41Since 2020-12-31Profile →
+12
Executives5
MG
Matthew Gline→
Chief Executive Officer
Age 41Since 2020-12-31
RP
Richard Pulik
Director of Finance/CFO
—Since 2021-09-27
MS
Mayukh Sukhatme→
President
Age 50Since 2020-12-31
EV
Eric Venker
President
Age 39Since 2020-12-31
DK
Drew Kramer
Chief Tech/Sci/R&D Officer
——
Board of directors8
KM
Keith Manchester→
Director/Board Member
Age 57Since 2013-12-31
IO
Ilan Oren→
Chairman
Age 42Since 2023-03-12
DG
Dan Gold→
Director/Board Member
Age 58Since 2019-12-31
MG
Matthew Gline→
Director/Board Member
Age 41—
MS
Mayukh Sukhatme→
Director/Board Member
Age 50Since 2023-11-09
ME
Melissa Epperly→
Director/Board Member
Age 48Since 2022-06-28
JM
James Momtazee→
Director/Board Member
—Since 2021-09-30
MF
Meghan Fitzgerald→
Director/Board Member
Age 55Since 2023-03-12
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| Dexcel Ltd. | 14.3 % | 102,849,443 |
| Fidelity Management & Research Co. LLC | 10.84 % | 77,973,345 |
| Morgan Stanley Investment Management, Inc. | 7.206 % | 51,828,325 |
| BlackRock Advisors LLC | 5.837 % | 41,983,305 |
| Vivek Ramaswamy | 3.55 % | 25,534,970 |
Catalog · 2026-07-09
Registry officers11
| Name | Role | Since | Shares |
|---|---|---|---|
| Ilan Oren | Chairman | 2023-03-12 | - |
| Dan Gold | Director/Board Member | 2019-12-31 | - |
| Ilan Oren Director and Chair | Director or executive officer | — | 232,044 |
| James Momtazee | Director/Board Member | 2021-09-30 | - |
| Keith Manchester | Director/Board Member | 2013-12-31 | - |
| Keith Manchester Director | Director or executive officer | — | 1,860,218 |
| Matthew Gline | Director/Board Member | — | - |
| Mayukh Sukhatme | Director/Board Member | 2023-11-09 | - |
Registry · as of 2026-09-16
Group companies
| Name | Category |
|---|---|
| Roivant Sciences GmbH | Pharmaceuticals: Major |
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus strong buyMean target 48.27Range 41–55Analysts 11
41Mean 48.2755
- Strong buy 2
- Buy 9
- Hold 2
Broker actions40 of 97
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| Wolfe Research | Downgrade | Peer Perform | — | 2026-10-12 |
| Stifel | Initiated | Buy | 51 | 2026-09-17 |
| TD Cowen | Maintained | Buy | 55 | 2026-09-09 |
| Guggenheim | Maintained | Buy | 46 | 2026-09-09 |
| HC Wainwright & Co. | Maintained | Buy | 47 | 2026-09-08 |
| Jefferies | Maintained | Buy | 52 | 2026-09-08 |
| HC Wainwright & Co. | Reiterated | Buy | 41 | 2026-08-28 |
| Citigroup | Maintained | Buy | 46 | 2026-08-10 |
| Guggenheim | Maintained | Buy | 42 | 2026-08-07 |
| HC Wainwright & Co. | Maintained | Buy | 41 | 2026-08-07 |
| Guggenheim | Maintained | Buy | 36 | 2026-05-26 |
| Citigroup | Maintained | Buy | 42 | 2026-05-21 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.